Jade Biosciences (NASDAQ:JBIO) Coverage Initiated at HC Wainwright

HC Wainwright started coverage on shares of Jade Biosciences (NASDAQ:JBIO) in a research note issued to investors on Wednesday, Marketbeat.com reports. The firm set a “buy” rating and a $25.00 price target on the stock. HC Wainwright’s target price would indicate a potential upside of 88.68% from the stock’s current price.

Several other research analysts also recently weighed in on JBIO. Weiss Ratings reiterated a “sell (e+)” rating on shares of Jade Biosciences in a research note on Monday, December 29th. Guggenheim lifted their price objective on shares of Jade Biosciences from $14.00 to $17.00 and gave the company a “buy” rating in a research report on Tuesday, November 18th. BTIG Research assumed coverage on shares of Jade Biosciences in a research note on Thursday, October 9th. They issued a “buy” rating and a $28.00 price objective on the stock. Finally, Wall Street Zen upgraded shares of Jade Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $20.80.

Jade Biosciences Stock Performance

NASDAQ JBIO opened at $13.25 on Wednesday. The firm has a market cap of $653.36 million, a PE ratio of -1.19 and a beta of 1.02. Jade Biosciences has a one year low of $6.57 and a one year high of $100.10. The firm’s fifty day moving average is $13.08 and its two-hundred day moving average is $10.16.

Jade Biosciences (NASDAQ:JBIO) last announced its earnings results on Friday, November 14th. The company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.09.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of JBIO. Deltec Asset Management LLC purchased a new stake in shares of Jade Biosciences during the 2nd quarter worth $157,000. Geode Capital Management LLC purchased a new position in shares of Jade Biosciences in the 2nd quarter valued at about $6,759,000. Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Jade Biosciences in the second quarter valued at about $71,000. Intech Investment Management LLC purchased a new stake in Jade Biosciences during the second quarter worth about $230,000. Finally, Versant Venture Management LLC acquired a new position in Jade Biosciences during the second quarter worth about $15,243,000.

About Jade Biosciences

Jade Biosciences, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small‐molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments.

The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation.